Sector Expert: Geert Kersten
Geert Kersten, chairman and CEO of CEL-SCI Corporation, has served in his current leadership role since 1995. He has been with CEL-SCI since its inception in 1987, and has been involved in the pioneering field of cancer immunotherapy for almost two decades. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law, and has a unique vision of how the company's Multikine product will change the way cancer is treated. Prior to CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble, and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from Millfield School in England and completed his studies in the US. His undergraduate degree in is in accounting. He also received a master's degree in business administration from George Washington University, and a law degree from American University in Washington, D.C.
CEL-SCI Corp.'s Novel Immunotherapies Set Sights on Cancer, Autoimmune Disorders and Infectious Diseases (2/19/15)
Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders has been limited. That paradigm is changing, and CEL-SCI Corp. is among the companies poised to bring immunotherapy into these disease spaces. In this interview with The Life Sciences Report, Geert Kersten, CEL-SCI's CEO, describes how his company's Multikine and L.E.A.P.S. platforms can be deployed, and how investors can turn an immunotherapeutic win into profit.